1-4 of 4
Hyun-Jin Nam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 865–877.
https://doi.org/10.1158/1535-7163.MCT-12-0950
Published: 09 June 2013
View article titled, RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Open the PDF for RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (1): 16–26.
https://doi.org/10.1158/1535-7163.MCT-12-0109
Published: 13 January 2013
View article titled, Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Open the PDF for Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Hyun-Jin Nam, Keith A. Ching, Julie Kan, Hwang-Phill Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, James G. Christensen, Do-Youn Oh, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 439–451.
https://doi.org/10.1158/1535-7163.MCT-11-0494
Published: 08 February 2012
View article titled, Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Open the PDF for Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Hyun‐Jin Nam, Hwang‐Phill Kim, Young‐Kwang Yoon, Hyung‐Seok Hur, Maeng‐Sup Kim, Gwan‐Sun Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B260.
https://doi.org/10.1158/1535-7163.TARG-09-B260
Published: 10 December 2009
View article titled, Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells